Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina

A phase 3 trial registered on ClinicalTrials.gov. The registry status is completed. It enrolled 1004 participants.

Also called NCT01659580

  • Study
  • In this atlas

Overview

Design
Interventional study; randomized; quadruple masking; primary purpose treatment
Phase
Phase 3
Enrolled
  • 1,004 participants (enrolled count) (from the registry)
Sponsor
Tasly Pharmaceuticals, Inc. (from the registry)
Registry
  • NCT NCT01659580
Start date
(registry gives no type) (from the registry)
Primary completion
(actual) (from the registry)
Completion
(actual) (from the registry)
Countries
United States, Belarus, Canada, Georgia, Mexico, Russia, Ukraine (from the registry)
Registry status
  • Completed (from the registry)

Technical summary

Registry record NCT01659580. Randomized; quadruple masking; primary purpose treatment. Start 2012-08 (registry gives no type); primary completion 2016-12 (actual). Results not posted.

The registry's words

Labels as the registry gives them, not rewritten.

Brief title
Phase III Trial of Dantonic® (T89) Capsule to Prevent and Treat Stable Angina
Acronym
CAESA
Condition
Angina Pectoris
Intervention (Drug)
T89 high dose
Intervention (Drug)
T89 Low dose
Intervention (Drug)
Sanqi+Bingpian
Intervention (Drug)
Placebo
Lead sponsor
Tasly Pharmaceuticals, Inc. (class: industry)

Record details

Record id
cardio:ct-nct01659580
Content hash
d56af27b0c5fe9839fbd44e38535f5a5d05a460ae8c5d6526f9fa84ebaeb08b8